# A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy

Study · id `cardio:ct-nct06220773` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06220773](<https://clinicaltrials.gov/study/NCT06220773>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06220773

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 276 participants.

## Technical summary

Registry record NCT06220773. Randomized; double masking; primary purpose treatment. Start 2024-05-21 (actual); primary completion 2026-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 276 participants (planned count; ClinicalTrials.gov record NCT06220773, source copy `cardio:ctgov-nct06220773-2026-10-16`, retrieved 2026-10-26)
- Started: 2024-05-21 (actual) (ClinicalTrials.gov record NCT06220773, source copy `cardio:ctgov-nct06220773-2026-10-16`, retrieved 2026-10-26)
- Primary completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT06220773, source copy `cardio:ctgov-nct06220773-2026-10-16`, retrieved 2026-10-26)
- Completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT06220773, source copy `cardio:ctgov-nct06220773-2026-10-16`, retrieved 2026-10-26)
- Countries: Indonesia; South Korea (ClinicalTrials.gov record NCT06220773, source copy `cardio:ctgov-nct06220773-2026-10-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06220773-2026-10-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy
- Condition: Essential Hypertension
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): BR1019A
- Intervention (Drug): BR1019B
- Intervention (Drug): BR1019C
- Intervention (Drug): BR1019A-1
- Intervention (Drug): BR1019B-1
- Intervention (Drug): BR1019C-1
- Lead sponsor: Boryung Pharmaceutical Co., Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Boryung Pharmaceutical Co., Ltd (`cardio:org-boryung-pharmaceutical-co-ltd`)

## Provenance

Content hash: eaa8a0fcd3b2f264e20d9f5473ace14aef3a4fb54c8d9fe709445d81995f2e8d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
